Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 382 net operating loss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback